RT Journal Article
T1 In Vitro and Ex Vivo Evaluation of Nepafenac-Based Cyclodextrin Microparticles for Treatment of Eye Inflammation
A1 Lorenzo Veiga, Blanca
A1 Díaz Rodríguez, Patricia
A1 Álvarez Lorenzo, Carmen
A1 Loftsson, Thorsteinn
A1 Sigurdsson, Hakon Hrafn
K1 Eye drop
K1 Cyclodextrin
K1 Nepafenac
K1 HET-CAM
K1 Ex vivo permeation studies
K1 Ocular inflammation
AB The aim of this study was to design and evaluate novel cyclodextrin (CD)-based aggregate formulations to efficiently deliver nepafenac topically to the eye structure, to treat inflammation and increase nepafenac levels in the posterior segment, thus attenuating the response of inflammatory mediators. The physicochemical properties of nine aggregate formulations containing nepafenac/γ-CD/hydroxypropyl-β (HPβ)-CD complexes as well as their rheological properties, mucoadhesion, ocular irritancy, corneal and scleral permeability, and anti-inflammatory activity were investigated in detail. The results were compared with a commercially available nepafenac suspension, Nevanac® 3 mg/mL. All formulations showed microparticles, neutral pH, and negative zeta potential (–6 to –27 mV). They were non-irritating and nontoxic and showed high permeation through bovine sclera. Formulations containing carboxymethyl cellulose (CMC) showed greater anti-inflammatory activity, even higher than the commercial formulation, Nevanac® 0.3%. The optimized formulations represent an opportunity for topical instillation of drugs to the posterior segment of the eye
PB MDPI
YR 2020
FD 2020
LK http://hdl.handle.net/10347/23634
UL http://hdl.handle.net/10347/23634
LA eng
NO Lorenzo-Veiga, B.; Diaz-Rodriguez, P.; Alvarez-Lorenzo, C.; Loftsson, T.; Sigurdsson, H.H. In Vitro and Ex Vivo Evaluation of Nepafenac-Based Cyclodextrin Microparticles for Treatment of Eye Inflammation. Nanomaterials 2020, 10, 709
NO This research was funded by MINECO (SAF2017-83118-R), Agencia Estatal de Investigación (AEI) Spain, Xunta de Galicia (ED431C 2016/008), and FEDER (Spain). B.L.-V. acknowledges an Erasmus+ traineeship (IS-SM2018-81075)
DS Minerva
RD 24 abr 2026